Organic Synthesis Pharmaceuticals plans to sell 25,325 shares of common stock at 346 yen per share on August 20, 2026, and introduce a new compensation system for directors and executive officers.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4531","jir_company_name":"Organic Synthesis Pharmaceuticals Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-21","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4531-20260721-01.pdf","jir_short_summary":"Organic Synthesis Pharmaceuticals plans to sell 25,325 shares of common stock at 346 yen per share on August 20, 2026, and introduce a new compensation system for directors and executive officers.","jir_summary":"### Overview of Share Buyback\nOn August 20, 2026, Organic Synthesis Pharmaceuticals will sell 25,325 shares of common stock at 346 yen per share as part of its Restricted Stock Compensation Plan. The purpose of the sale is to enhance corporate value sustainably and provide incentives to officers. The shares to be sold will be managed in a dedicated account by a financial instruments business operator. The total sale amount is 8,762,450 yen, set based on the market stock price.\n\n### Background and Details of the Compensation System Introduction\nSimultaneously, the company will introduce a Restricted Stock Compensation Plan for eligible directors and executive officers, with transfer restrictions imposed for a certain period and provisions for free acquisition upon retirement. The system will commence on August 20, 2026, with transfer restrictions lifted at retirement, and the shares will be acquired free of charge. This aims to promote officers' commitment to long-term corporate value enhancement.","jir_financial_highlights":"Number of Shares Sold: 25,325 shares (Unknown)\nTotal Sale Price: 8,762,450 yen (Unknown)\nPrice per Share: 346 yen (Unknown)","jir_category":"","jir_hashtags":"#OrganicSynthesisPharmaceuticals, #IRRelated, #JapanStocks","jir_key_figures":"Number of Shares Sold: 25,325 shares\nTotal Sale Price: 8,762,450 yen\nPrice per Share: 346 yen","jir_meta_title":"\u3010Organic Synthesis Pharmaceuticals\u3011Share Buyback and Introduction of Compensation System | July 2026","jir_meta_description":"Organic Synthesis Pharmaceuticals plans to sell 25,325 shares of common stock at 346 yen per share in August 2026 and introduce a new compensation system for officers. The initiative aims to enhance long-term value.","jir_og_title":"\u3010Organic Synthesis Pharmaceuticals\u3011Share Buyback and Introduction of Compensation System | July 2026","jir_og_description":"Organic Synthesis Pharmaceuticals will conduct a share buyback and introduce a new compensation system in August 2026 to strengthen corporate value and officer incentives.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59377,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_cancellation","footnotes":""},"sector":[],"importance":[],"class_list":["post-85851","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n